MDL | MFCD05662337 |
---|---|
Molecular Weight | 321.82 |
Molecular Formula | C16H16ClNO2S |
SMILES | ClC1=C(C=CC=C1)[C@H](N2CCC3=C(C2)C=CS3)C(OC)=O |
Clopidogrel is an orally active platelet inhibitor that targets P2Y12 receptor. Clopidogrel is used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.
P2Y12 receptor [1] .
Clopidogrel, administered during the last three months, significantly decreases blood glucose, collagen and fibronectin expression compared to vehicle-treated diabetic mice. Clopidogrel markedly ameliorates hyperglycemia-induced renal fibrosis [1] . The combination therapy of clopidogrel and aspirin (dual-antiplatelet therapy) has been shown to be significantly beneficial compared to aspirin monotherapy and has also shown to decrease sub-acute stent thrombosis as well as recurrent ischemic events following ACS [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT02052635 | AstraZeneca |
Non-ST Elevation Acute Coronary Syndrome
|
September 2014 | Phase 4 |
NCT00661206 | Deutsches Herzzentrum Muenchen |
Coronary Artery Disease
|
September 2008 | Phase 4 |
NCT04069234 | Region Skane|IHF GmbH - Institut für Herzinfarktforschung|Hippocrates Research|IRW consulting AB|AstraZeneca |
Diabetes Mellitus|Microvascular Coronary Artery Disease
|
September 15, 2019 | Phase 3 |
NCT02612480 | Radboud University Medical Center |
Endotoxemia
|
October 2015 | Not Applicable |
NCT00421252 | Beth Israel Deaconess Medical Center |
Coronary Artery Disease|Myocardial Ischemia|Bleeding
|
January 2007 | Phase 4 |
NCT00799396 | University of Maryland, Baltimore|National Institute of General Medical Sciences (NIGMS)|National Heart, Lung, and Blood Institute (NHLBI) |
Platelet Aggregation Inhibitors|Coronary Heart Disease
|
July 2006 | Phase 4 |
NCT01586975 | Northwestern University |
Stroke|Myocardial Infarctions
|
July 2007 | Phase 2|Phase 3 |
NCT02071966 | Catholic University of the Sacred Heart |
Non ST Segment Elevation Acute Coronary Syndrome
|
November 2012 | Phase 4 |
NCT04078737 | Beijing Tiantan Hospital|Ministry of Science and Technology of the People´s Republic of China |
Stroke|Transient Ischemic Attack
|
September 23, 2019 | Phase 3 |
NCT00296803 | Sanofi|Bristol-Myers Squibb |
Metabolic Syndrome x
|
November 2005 | Phase 4 |
NCT04695106 | Medical University of Gdansk|Medical University of Warsaw|Nicolaus Copernicus University|Institute of Cardiology, Warsaw, Poland|Military Institute of Medicine, Poland|Bielanski Hospital|Medical University of Silesia|Poznan University of Medical Sciences|University of Opole, Poland|Medical University of ?ód?|Voivodeship Hospital, Kielce, Poland|Voivode Specialist Hospital in Olsztyn, Poland|Medical University of Lublin|Pomeranian Medical University Szczecin|Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland |
Atrial Fibrillation|Antithrombotic Therapy|Acute Coronary Syndrome|Percutaneous Coronary Interventions
|
October 25, 2021 | Phase 4 |
NCT02265289 | Boehringer Ingelheim |
Healthy
|
January 1999 | Phase 1 |
NCT02415803 | First Affiliated Hospital of Harbin Medical University |
Non ST Segment Elevation Acute Coronary Syndrome
|
December 2014 | Phase 3 |
NCT03463317 | Charite University, Berlin, Germany|Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)|Atrial Fibrillation Network|Stiftung Institut fuer Herzinfarktforschung |
Atrial Fibrillation
|
February 28, 2018 | Phase 4 |
NCT05320926 | Yonsei University |
Ischemic Heart Disease
|
March 11, 2022 | Not Applicable |
NCT00404781 | Shenyang Northern Hospital |
Ischemic Heart Disease|Acute Coronary Syndromes
|
June 2006 | Phase 4 |
NCT00623623 | Boehringer Ingelheim |
Myocardial Infarction
|
March 1, 2008 | Phase 3 |
NCT01657071 | Yuhan Corporation |
Acute Coronary Syndrome
|
March 2012 | Phase 1 |
NCT01325935 | Associations for Establishment of Evidence in Interventions|Medtronic |
Coronary Artery Disease
|
April 2011 | Phase 4 |
NCT03198741 | Shenyang Northern Hospital|Changhai Hospital|ANKON medical technologies (Shanghai)Co.,LTD |
Gastrointestinal Injury|Ischemic Heart Disease
|
July 13, 2017 | Phase 4 |
NCT01765400 | University of Nebraska|Daiichi Sankyo, Inc.|Eli Lilly and Company |
Systolic Heart Failure
|
February 2013 | Phase 4 |
NCT00620646 | Samsung Medical Center |
Clopidogrel Non-Responsiveness
|
February 2008 | Not Applicable |
NCT04060914 | Beijing Anzhen Hospital |
Antiplatelet Therapy|Coronary Artery Disease|Percutaneous Coronary Intervention
|
August 30, 2019 | Phase 4 |
NCT02244710 | Fundación Investigación Sanitaria en León|AstraZeneca |
Acute Coronary Syndrome (ACS)
|
March 2015 | Not Applicable |
NCT00222573 | University of Oxford|Sanofi|AstraZeneca |
Acute Myocardial Infarction
|
July 1999 | Phase 4 |
NCT02618733 | Dong-A University|AstraZeneca|Biotronik SE & Co. KG |
Acute Coronary Syndrome
|
December 2014 | Not Applicable |
NCT03207451 | Inova Health Care Services|Merck Sharp & Dohme LLC |
Coronary Artery Disease|Peripheral Vascular Disease|Myocardial Infarction
|
January 1, 2016 | Phase 4 |
NCT00140465 | Deutsches Herzzentrum Muenchen|Technical University of Munich |
Coronary Disease
|
October 2004 | Phase 4 |
NCT01621763 | Dr. Reddy´s Laboratories Limited |
Healthy
|
September 2008 | Phase 1 |
NCT01233167 | Sir Run Run Shaw Hospital |
Coronary Artery Disease
|
August 2011 | Not Applicable |
NCT04688723 | Zuyderland Medisch Centrum|Boehringer Ingelheim |
Coronary Artery Disease|Myocardial Ischemia|Myocardial Infarction|Atrial Fibrillation
|
December 23, 2020 | Phase 4 |
NCT02677545 | University Hospital, Basel, Switzerland |
Carotid Artery Stenosis
|
December 2016 | Phase 2 |
NCT01584791 | Seoul National University Hospital|Hanmi Pharmaceutical co., ltd. |
Coronary Artery Disease
|
October 2010 | Phase 4 |
NCT04981041 | Ludwig-Maximilians - University of Munich |
Acute Coronary Syndrome|Atrial Fibrillation
|
December 16, 2021 | Phase 4 |
NCT02133989 | Samsung Medical Center|Yuyu Pharma, Inc. |
Carotid Stenosis
|
June 2014 | Phase 3 |
NCT05209412 | Xijing Hospital |
De Novo Stenosis|Coronary Artery Disease|Percutaneous Coronary Intervention
|
February 1, 2022 | Not Applicable |
NCT05504330 | Anhui Medical University |
Asymptomatic Intracranial Stenosis|Cognitive Impairment|Cerebrovascular Event
|
August 15, 2022 | |
NCT01267734 | Seoul National University Hospital|Boston Scientific Corporation |
Coronary Heart Disease
|
June 2010 | Phase 4 |
NCT02792712 | Taipei Veterans General Hospital, Taiwan |
Acute Coronary Syndrome
|
January 2016 | Phase 4 |
NCT04418479 | Joo-Yong Hahn|Samsung Medical Center |
Coronary Artery Disease
|
August 10, 2020 | Phase 4 |
NCT02294643 | Seoul National University Bundang Hospital|Yuhan Corporation |
Coronary Artery Disease|Diabetes Mellitus|Renal Insufficiency, Chronic
|
April 2009 | Phase 3 |
NCT01826175 | Massachusetts General Hospital|AstraZeneca |
Acute Coronary Syndrome|Coronary Artery Disease
|
May 2013 | Phase 4 |
NCT02560688 | Daiichi Sankyo, Inc. |
Drug Interaction
|
December 2015 | Phase 1 |
NCT02391883 | Hvidovre University Hospital |
Hip Fracture
|
January 2011 | |
NCT00751491 | University of Roma La Sapienza |
Stable Angina|Percutaneous Coronary Intervention
|
September 2008 | Phase 3 |
NCT01338909 | University of Patras |
Myocardial Infarction
|
April 2011 | Phase 3 |
NCT04630288 | Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Andalusian Network for Design and Translation of Advanced Therapies |
Acute Coronary Syndromes
|
July 2, 2019 | |
NCT00914368 | Uppsala University |
Coronary Artery Disease|Myocardial Infarction|Stent Thrombosis|Heart Diseases|Acute Coronary Syndrome
|
January 2009 | Phase 2 |
NCT00774475 | University of Florence|Tuscany Region |
Unstable Angina|NSTEMI
|
November 2008 | Phase 3 |
NCT00007683 | US Department of Veterans Affairs|Sanofi-Synthelabo|Bristol-Myers Squibb|VA Office of Research and Development |
Heart Failure
|
October 1998 | Phase 3 |
NCT00716924 | Sanofi|Bristol-Myers Squibb |
Thrombosis
|
May 2004 | Phase 3 |
NCT01032668 | Bursa Postgraduate Hospital |
Coronary Artery Disease
|
September 2008 | Phase 3 |
NCT02376283 | The Royal Wolverhampton Hospitals NHS Trust |
Heart Attack
|
March 9, 2015 | Phase 4 |
NCT00097591 | Eli Lilly and Company|Daiichi Sankyo, Inc. |
Coronary Arteriosclerosis|Acute Coronary Syndromes
|
November 2004 | Phase 3 |
NCT02606552 | Yonsei University |
Atrial Fibrillation|Coronary Artery Disease
|
July 20, 2016 | Phase 4 |
NCT00404053 | Shenyang Northern Hospital |
Acute Coronary Syndrome
|
December 2004 | Phase 4 |
NCT00891670 | Gyeongsang National University Hospital |
Coronary Artery Stenosis|Maximal Platelet Aggregation|Late Platelet Aggregation|High Post-Treatment Platelet Reactivity
|
May 2009 | Phase 3 |
NCT04484259 | University of Florida|AstraZeneca |
Diabetes Mellitus, Type 2|Coronary Artery Disease
|
March 31, 2021 | Phase 4 |
NCT01805596 | Lawson Health Research Institute |
Coronary Artery Disease|Endothelial Function
|
April 2013 | Phase 3 |
NCT03245489 | Medical University of South Carolina |
Head and Neck Cancer
|
October 20, 2017 | Phase 1 |
NCT02617290 | Assistance Publique - Hôpitaux de Paris|Action Research Group|AstraZeneca |
Coronary Artery Disease|Myocardial Ischemia|Myocardial Infarction|Stent Thrombosis|Cardiovascular Diseases
|
January 9, 2017 | Phase 3 |
NCT00115375 | Sanofi|Bristol-Myers Squibb |
Congenital Heart Defects|Blood Platelet Disorders
|
January 2004 | Phase 2 |
NCT03161678 | University of Maryland, Baltimore |
Myocardial Infarction|Thrombosis|Platelet Dysfunction
|
August 22, 2017 | Phase 4 |
NCT01456546 | University of Southern Denmark |
CYP2C19 Genotypes
|
October 2011 | Phase 1 |
NCT03103685 | Chiang Mai University |
Dental Diseases|Antiplatelet Agents|Antiplatelet Drugs
|
May 1, 2017 | Phase 4 |
NCT03381742 | First Affiliated Hospital of Harbin Medical University|Beijing Anzhen Hospital|The First Affiliated Hospital of Dalian Medical University|The Central Hospital of Jia Mu Si City|The First Affiliated Hospital of Kunming Medical College|RenJi Hospital|Tianjin Medical University General Hospital|Weifang People´s Hospital|Wuhan Union Hospital, China|Shengjing Hospital|Shaanxi Provincial People´s Hospital |
Coronary Artery Disease
|
December 13, 2017 | Phase 2|Phase 3 |
NCT00153062 | Boehringer Ingelheim|GlaxoSmithKline|Bayer |
Stroke
|
August 2003 | Phase 4 |
NCT01523392 | AstraZeneca |
Stable Coronary Artery Disease
|
March 2012 | Phase 4 |
NCT02429271 | Hellenic Cardiovascular Research Society |
Myocardial Infarction|ST Segment Elevation Myocardial Infarction (STEMI)
|
August 2015 | Phase 3 |
NCT02711410 | National Cerebral and Cardiovascular Center |
Platelet Aggregation Inhibitors
|
October 2009 | |
NCT01543932 | University of Roma La Sapienza |
Coronary Artery Disease
|
July 2012 | Phase 3 |
NCT03679091 | First Affiliated Hospital of Harbin Medical University |
Platelet Reactivity
|
August 29, 2018 | Phase 4 |
NCT00642174 | Eli Lilly and Company|Daiichi Sankyo, Inc. |
Diabetes Mellitus|Coronary Artery Disease
|
April 2008 | Phase 2 |
NCT02975076 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine |
Stroke, Acute|Ischemic Attack, Transient
|
December 2016 | Not Applicable |
NCT02499666 | Henry Ford Health System |
Coronary Artery Disease|Angina Pectoris
|
June 29, 2015 | |
NCT02209350 | Meshalkin Research Institute of Pathology of Circulation |
Aorta-iliac Segment Lesion (C,D Type by TASC II)
|
August 2, 2014 | Phase 1 |
NCT00152724 | University Hospital, Angers |
Healthy Volunteers
|
January 1996 | |
NCT01642238 | Juan J Badimon|AstraZeneca|Icahn School of Medicine at Mount Sinai |
Acute Coronary Syndrome
|
July 2012 | Phase 4 |
NCT02578537 | Shenyang Northern Hospital |
Non ST Segment Elevation Acute Coronary Syndrome|Chronic Kidney Disease
|
October 2015 | Phase 4 |
NCT01037491 | Taipei Veterans General Hospital, Taiwan |
Gastric Ulcer|Duodenal Ulcer
|
October 2009 | Not Applicable |
NCT01924325 | Xijing Hospital |
Ischemic Stroke|TIA
|
January 2014 | Phase 2|Phase 3 |
NCT01118325 | AstraZeneca |
Stable Coronary Artery Disease
|
April 2010 | Phase 2 |
NCT01959191 | Yonsei University |
Coronary Artery Disease
|
January 2008 | |
NCT02217501 | University of Texas Southwestern Medical Center |
Peripheral Arterial Disease
|
November 2015 | Phase 3 |
NCT02626169 | Baylor College of Medicine |
Atherosclerosis
|
December 2015 | Phase 4 |
NCT02224274 | University Medical Centre Ljubljana |
Cardiac Arrest|Postresuscitation Syndrome|Myocardial Infarction (ST-Elevation Myocardial Infarction and Non-ST-Elevation Myocardial Infarction)
|
August 2014 | Phase 4 |
NCT00589862 | Creighton University |
Coronary Artery Disease
|
October 2007 | Phase 4 |
NCT00776477 | China National Center for Cardiovascular Diseases |
Atherosclerosis
|
December 2007 | Phase 3 |
NCT00687076 | Baylor College of Medicine|National Heart, Lung, and Blood Institute (NHLBI) |
Peripheral Arterial Disease
|
April 2004 | Phase 4 |
NCT02594410 | Lee´s Pharmaceutical Limited |
Hypertension
|
September 2011 | Phase 4 |
NCT04850001 | Anhui Medical University |
Magnetic Resonance Imaging|Asymptomatic Intracranial Stenosis|Medical Treatment
|
September 10, 2020 | |
NCT01103440 | Icahn School of Medicine at Mount Sinai |
Stable Angina
|
April 2007 | Phase 2 |
NCT00833703 | Sanofi|Bristol-Myers Squibb |
Heart Defects, Congenital
|
January 2009 | Phase 3 |
NCT02048085 | Medical Center of South Arkansas |
Acute ST Segment Elevation Myocardial Infarction|Acute Coronary Syndrome
|
January 2, 2014 | Phase 4 |
NCT00650169 | Mylan Pharmaceuticals Inc|MylanPharma |
Healthy
|
December 2004 | Phase 1 |
NCT00857155 | LifeBridge Health |
Coronary Artery Disease
|
January 2009 | Not Applicable |
NCT01108588 | Merck Sharp & Dohme LLC |
Healthy Volunteers
|
June 2010 | Phase 1 |
NCT02037412 | Yonsei University |
Acute Coronary Syndrome|Acute Myocardial Infarction|Unstable Angina (Intermediate Coronary Syndrome)
|
January 2014 | Phase 4 |
NCT04624854 | Harbin Medical University|Chinese Society of Cardiology|Lepu Medical Technology (Beijing) Co., Ltd. |
Coronary Artery Disease|Myocardial Ischemia|Acute Coronary Syndrome|Heart Diseases|Syndrome Heart Disease|Cardiovascular Diseases|Arteriosclerosis|Arterial Occlusive Diseases|Coronary Disease|Vascular Diseases
|
October 27, 2020 | Phase 4 |
NCT01304472 | University of Patras |
Coronary Artery Disease (CAD)
|
February 2011 | Phase 3 |
NCT01449617 | Azienda Ospedaliera di Perugia|University Of Perugia |
Carotid Artery Disease
|
August 2010 | |
NCT00827346 | Ottawa Heart Institute Research Corporation |
Platelet Reactivity
|
January 2009 | Phase 2|Phase 3 |
NCT02960126 | Chuncheon Sacred Heart Hospital |
Atrial Fibrillation
|
November 2016 | Phase 3 |
NCT00751231 | Portola Pharmaceuticals |
Percutaneous Coronary Intervention
|
December 2008 | Phase 2 |
NCT01823185 | Imam Abdulrahman Bin Faisal University|King Fahad Armed Forces Hospital|Dammam Central Hospital |
Coronary Artery Disease|Myocardial Infarction|Heart Disease|Vascular Disease|Angina Pectoris|Cardiovascular Disease|Ischemia|Infarction|Embolism|Thrombosis|Chest Pain
|
March 2013 | Phase 4 |
NCT02506140 | Beijing Tiantan Hospital|Beijing Municipal Science & Technology Commission |
Stroke|Ischemic Attack, Transient
|
August 2015 | Phase 2|Phase 3 |
NCT01641510 | Dong-A University |
Acute Coronary Syndromes
|
October 2013 | Phase 3 |
NCT00224809 | Baylor Research Institute|National Heart, Lung, and Blood Institute (NHLBI) |
Cardiovascular Diseases|Heart Diseases|Coronary Disease
|
September 2002 | Not Applicable |
NCT01757262 | AstraZeneca |
Coronary Heart Disease
|
January 2013 | Phase 3 |
NCT00406991 | Schepens Eye Research Institute|Massachusetts Eye and Ear Infirmary |
Diabetes|Diabetic Retinopathy
|
June 2003 | Phase 2 |
NCT01452152 | University of Maryland, Baltimore|National Heart, Lung, and Blood Institute (NHLBI) |
Cardiovascular Diseases|Acute Coronary Syndrome
|
February 2012 | Phase 4 |
NCT04847752 | Tongji Hospital |
Ischemic Stroke|Large-Artery Atherosclerosis (Embolus+Thrombosis)
|
March 1, 2021 | |
NCT01778842 | Gennaro Sardella|University of Roma La Sapienza |
Coronary Artery Disease
|
March 2013 | Phase 3 |
NCT05353140 | Xijing Hospital |
Atrial Fibrillation|Percutaneous Coronary Intervention
|
September 1, 2022 | Not Applicable |
NCT01469416 | University of California, San Francisco |
Healthy
|
March 2012 | Phase 1 |
NCT00827411 | Assistance Publique - Hôpitaux de Paris|Allies in Cardiovascular Trials Initiatives and Organized|Institut National de la Santé Et de la Recherche Médicale, France|Sanofi|Bristol-Myers Squibb|Medtronic|Cordis Corporation|Fondation de France|Diagnostica Stago|Boston Scientific Corporation |
Coronary Artery Disease|Acute Coronary Syndrome
|
January 2009 | Phase 4 |
NCT04229264 | Science Valley Research Institute|Wyeth is now a wholly owned subsidiary of Pfizer |
Critical Limb Ischemia
|
January 9, 2020 | Phase 3 |
NCT03224923 | Ottawa Heart Institute Research Corporation |
Stable Coronary Syndrome|Percutaneous Coronary Intervention|Antiplatelet Therapy|Ticagrelor
|
August 18, 2017 | Phase 4 |
NCT01887704 | Capital Medical University|Beijing Anzhen Hospital |
Coronary Artery Disease
|
January 2010 | Not Applicable |
NCT01823510 | Juan J Badimon|AstraZeneca|Icahn School of Medicine at Mount Sinai |
Type-2 Diabetes Mellitus|Coronary Artery Disease
|
July 2013 | Phase 4 |
NCT02570581 | Centre Hospitalier Universitaire de Nice |
Healthy
|
June 2014 | Phase 1 |
NCT03431142 | Shenyang Northern Hospital |
Prolonged DAPT in ACS Patients With Hisk of Both Ischemic and Hemorrhage
|
February 12, 2018 | Phase 4 |
NCT02293395 | Janssen Research & Development, LLC|Bayer|Duke Clinical Research Institute|Harvard Medical School (HMS and HSDM) |
Acute Coronary Syndrome
|
April 20, 2015 | Phase 2 |
NCT02262650 | Boehringer Ingelheim |
Healthy
|
April 2004 | Phase 1 |
NCT01509365 | Les Laboratoires des Médicaments Stériles|University Hospital Fattouma Bourguiba |
Cardiovascular Disease|Overweight
|
December 2011 | Phase 4 |
NCT02260622 | Ottawa Hospital Research Institute|The Ottawa Hospital |
Critical Limb Ischemia
|
October 2014 | Phase 2 |
NCT00566891 | S. Anna Hospital |
Coronary Artery Disease
|
December 2007 | Phase 4 |
NCT00413608 | Assistance Publique - Hôpitaux de Paris |
Healthy
|
January 2007 | Phase 1 |
NCT01744288 | AstraZeneca |
Inhibition on Platelet Aggregation
|
December 2012 | Phase 1 |
NCT01515345 | Kaiser Franz Josef Hospital |
Platelet Inhibition|Coronary Stent Implantation
|
July 2011 | Phase 3 |
NCT01830543 | Janssen Scientific Affairs, LLC|Bayer |
Atrial Fibrillation|Percutaneous Coronary Intervention
|
May 10, 2013 | Phase 3 |
NCT01157455 | CCRF Consulting Co., Ltd. |
Coronary Artery Diseases
|
May 2010 | Phase 4 |
NCT04023630 | Second Affiliated Hospital, School of Medicine, Zhejiang University |
Atrial Fibrillation|Acute Coronary Syndromes
|
October 1, 2019 | Phase 4 |
NCT03581409 | Seoul National University Hospital|Seoul National University Bundang Hospital |
Aneurysm, Cerebral|Endovascular Procedures
|
October 24, 2018 | Phase 4 |
NCT03437044 | University of Florida|AstraZeneca |
Diabetes Mellitus, Type 2|Coronary Artery Disease
|
March 14, 2018 | Phase 4 |
NCT04237922 | Brigham and Women´s Hospital |
Antiplatelet
|
September 22, 2019 | |
NCT00368238 | Yale University|American Heart Association |
Healthy Subjects
|
October 2005 | Phase 2 |
NCT04501900 | Shanghai Zhongshan Hospital |
Cardiovascular Diseases
|
October 2020 | Phase 4 |
NCT02953405 | Daewoong Pharmaceutical Co. LTD. |
MCA - Middle Cerebral Artery Dissection
|
December 2015 | |
NCT02798874 | Chinese PLA General Hospital |
Cardiovascular Diseases
|
May 2016 | Not Applicable |
NCT01135667 | Lene Holmvang|Rigshospitalet, Denmark |
Coronary Artery Disease|Percutaneous Coronary Intervention|Acute Coronary Syndromes
|
September 2010 | Phase 4 |
NCT02120092 | Medical University of Vienna |
Acute Coronary Syndrome
|
October 2010 | Phase 2 |
NCT03729401 | Ottawa Heart Institute Research Corporation |
Coronary Artery Disease|Myocardial Infarction
|
August 22, 2019 | Phase 4 |
NCT00822536 | Assistance Publique - Hôpitaux de Paris|Fédération Française de Cardiologie |
Coronary Artery Disease|Stent Thrombosis|Myocardial Ischemia
|
January 2009 | Phase 4 |
NCT02185534 | AstraZeneca |
Bioequivalence, AUC, Cmax, Pharmacokinetics
|
August 2014 | Phase 1 |
NCT01665235 | RenJi Hospital |
Blood Pressure Variability|Intracranial Artery Stenosis
|
August 2012 | Not Applicable |
NCT00385138 | The Medicines Company |
Atherosclerosis|Acute Coronary Syndrome (ACS)
|
September 2006 | Phase 3 |
NCT02689037 | The 476th Hospital of People´s Liberation Army |
Intracranial Atherosclerosis
|
April 2016 | Phase 3 |
NCT05122455 | University of Sao Paulo|Daiichi Sankyo, Inc. |
SCAD|AMI
|
September 14, 2021 | Phase 2|Phase 3 |
NCT03188705 | University of Maryland, Baltimore |
Heart Diseases|Coronary Disease|Coronary Artery Disease|Cardiovascular Diseases|Myocardial Ischemia|Artery Occlusion|Aspirin Sensitivity|Clopidogrel, Poor Metabolism of|Platelet Dysfunction|Platelet Thrombus
|
October 14, 2019 | Phase 4 |
NCT00638326 | University of Pecs |
Stable Angina Pectoris|Ad Hoc Percutaneous Coronary Intervention
|
March 2008 | Phase 3 |
NCT01129271 | Sanofi|Bristol-Myers Squibb |
Healthy
|
April 2009 | Phase 1 |
NCT03392051 | Akcea Therapeutics |
Elevated Lipoprotein(a)|Cardiovascular Diseases
|
December 28, 2017 | Phase 1 |
NCT01327534 | Stiftung Institut fuer Herzinfarktforschung|Daiichi Sankyo, Inc. |
Myocardial Infarction|STEMI
|
May 2011 | Phase 3 |
NCT03691688 | Shanghai Zhongshan Hospital |
Coronary Artery Disease|Hyperuricemia
|
December 1, 2018 | |
NCT03787927 | Bloodworks|National Blood Foundation |
Bleeding|Platelet Dysfunction Due to Drugs|Platelet Dysfunction
|
December 3, 2018 | Phase 1|Phase 2 |
NCT05566301 | IRCCS Policlinico S. Donato |
Clopidogrel, Poor Metabolism of|Carotid Stenosis
|
September 2, 2021 | |
NCT01994941 | The University of Hong Kong |
Acute Coronary Syndrome
|
August 2013 | Phase 4 |
NCT00444132 | Sheba Medical Center |
Clopidogrel Non-Responsiveness
|
March 2005 | Phase 3 |
NCT04734028 | Gyeongsang National University Hospital|Korean Society of Interventional Cardiology |
Coronary Artery Disease|Clopidogrel, Poor Metabolism of|Platelet Dysfunction|Stent Thrombosis
|
July 9, 2003 | |
NCT01294462 | AstraZeneca |
Acute Coronary Syndrome|Percutaneous Coronary Intervention
|
February 2011 | Phase 3 |
NCT04237935 | Brigham and Women´s Hospital |
Antiplatelet
|
September 22, 2019 | |
NCT02696330 | Ain Shams Maternity Hospital |
Female , Infertility
|
September 2015 | Phase 4 |
NCT04809818 | Lumosa Therapeutics Co., Ltd. |
Acute Ischemic Stroke
|
March 21, 2021 | Phase 1 |
NCT00300339 | Sanofi |
Intermittent Claudication
|
February 2006 | Phase 2 |
NCT01789814 | Tufts Medical Center |
Coronary Artery Disease
|
July 2013 | Phase 4 |
NCT01526122 | Dong-A ST Co., Ltd. |
Atherosclerosis
|
September 2011 | Phase 1 |
NCT02096419 | University of Zagreb|Clinical Hospital Centre Zagreb|Ministry of Science, Education and Sport, Republic of Croatia |
Acute Coronary Syndrome
|
February 2012 | Phase 4 |
NCT05476081 | University of L´Aquila |
Ischemic Stroke|TIA
|
February 3, 2021 | |
NCT01158703 | Ahmad Slim|Bristol-Myers Squibb|Brooke Army Medical Center |
Coronary Graft Patency
|
July 2010 | Phase 4 |
NCT03289520 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|The Cleveland Clinic|Boston University|Duke University|University of Iowa|MaineHealth|University of Texas Southwestern Medical Center|University of Alabama at Birmingham|Washington University School of Medicine|Baystate Medical Center|Vanderbilt University|CAMC Health System|Emory University|St. Louis University|Tyler Nephrology Associates|Vascular Surgery Associates LLC |
Kidney Failure|Hemodialysis Fistula Thrombosis
|
January 7, 2003 | Phase 3 |
NCT01113372 | Cardiovascular Research Center, Brazil|Medtronic |
Coronary Artery Disease
|
April 2010 | Phase 4 |
NCT02317198 | St. Antonius Hospital|UMC Utrecht|Leiden University Medical Center|Meander Medical Center|Medical Center Alkmaar|Isala|Gelre Hospitals|Gelderse Vallei Hospital|Medical Centre Leeuwarden|Rijnstate Hospital |
Non-ST-elevation Acute Coronary Syndrome|Unstable Angina|Non-ST-elevation Myocardial Infarction
|
June 2013 | Phase 4 |
NCT01118793 | Scripps Health|National Center for Research Resources (NCRR) |
Coronary Artery Disease
|
December 2008 | |
NCT01496261 | Chong Kun Dang Pharmaceutical|Inje University |
Coronary Artery Disease
|
August 2011 | Phase 1 |
NCT04561739 | Xijing Hospital |
De Novo Stenosis|Coronary Artery Disease
|
February 1, 2021 | Not Applicable |
NCT00991029 | University of California, San Francisco|Neurological Emergencies Treatment Trials Network (NETT)|Medical University of South Carolina|The Emmes Company, LLC |
Ischemic Attack, Transient
|
May 28, 2010 | Phase 3 |
NCT01538446 | Assistance Publique - Hôpitaux de Paris|Eli Lilly and Company|Daiichi Sankyo, Inc.|Allies in Cardiovascular Trials Initiatives and Organized|Accumetrics, Inc.|Stentys |
Acute Coronary Syndrome
|
March 2012 | Phase 4 |
NCT05493657 | Yonsei University |
Severe Aortic Stenosis
|
September 15, 2022 | Not Applicable |
NCT02777580 | KU Leuven|Boehringer Ingelheim|Life Sciences Research Partners|Fund for Clinical Cardiovascular Research at LRD |
Myocardial Infarction
|
August 1, 2017 | Phase 4 |
NCT00940784 | Ronald Hoffman|Myeloproliferative Disorders-Research Consortium|National Cancer Institute (NCI)|Icahn School of Medicine at Mount Sinai |
Polycythemia Vera
|
June 2009 | Phase 2 |
NCT02513004 | Yongjian Wu|Chinese Academy of Medical Sciences, Fuwai Hospital |
Coronary Disease
|
June 2015 | Phase 4 |
NCT04671069 | Madrigal Pharmaceuticals, Inc. |
Healthy
|
July 26, 2019 | Phase 1 |
NCT01493999 | University of Pecs |
Acute Coronary Syndrome
|
September 2011 | Phase 4 |
NCT04822363 | Beth Israel Deaconess Medical Center|National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health (NIH) |
Platelet Activation Testing Before+After Anti-platelet Therapy|Healthy
|
August 20, 2021 | Early Phase 1 |
NCT00189618 | Arteriogenesis Competence Network |
Peripheral Arterial Disease
|
May 2005 | Phase 4 |
NCT04770012 | Ottawa Heart Institute Research Corporation|Canadian Institutes of Health Research (CIHR) |
Cardiac Allograft Vasculopathy|Heart Transplant
|
June 28, 2021 | Phase 3 |
NCT02459288 | Ping-Yen Liu|National Cheng-Kung University Hospital |
Acute Coronary Syndrome|Chronic Kidney Disease|End-Stage Renal Disease
|
January 2014 | Phase 4 |
NCT00699998 | Eli Lilly and Company|Daiichi Sankyo Co., Ltd.|Duke Clinical Research Institute |
Acute Coronary Syndrome
|
June 2008 | Phase 3 |
NCT04698031 | VA Office of Research and Development |
Silent Brain Infarction
|
March 30, 2022 | Phase 4 |
NCT01732822 | AstraZeneca |
Peripheral Artery Disease
|
December 4, 2012 | Phase 3 |
NCT00662467 | Hamilton Health Sciences Corporation|McMaster University |
Myocardial Infarction
|
November 2006 | Not Applicable |
NCT04407312 | Gyeongsang National University Hospital|Korea Otsuka Pharmaceutical Co., Ltd. |
Myocardial Infarction, Acute
|
January 1, 2016 | Phase 4 |
NCT05193071 | General Hospital of Shenyang Military Region |
Ischemic Stroke
|
July 8, 2022 | Phase 4 |
NCT02457130 | Spanish Society of Cardiology|AstraZeneca |
Coronary Artery Disease|Diabetes Mellitus. Type 2
|
April 2015 | Phase 4 |
NCT03649711 | University of Arkansas|American Society of Nephrology |
Chronic Kidney Diseases|Heart Attack|Stroke, Ischemic
|
November 1, 2018 | Phase 3 |
NCT01112137 | University of Cologne |
Blood Pressure|Endothelial Function|Platelet Function
|
January 2005 | Phase 4 |
NCT00004564 | National Center for Research Resources (NCRR) |
Hypercholesterolemia|Thrombosis
|
Not Applicable | |
NCT00732290 | Centre Hospitalier Universitaire de Saint Etienne |
Healthy
|
February 2009 | Phase 1 |
NCT01779401 | Chinese Academy of Medical Sciences, Fuwai Hospital|Beijing Municipal Health Bureau|Haemonetics Corporation|Zhejiang Otsuka Pharmaceutical Co., Ltd. |
Coronary Heart Disease
|
September 2012 | Not Applicable |
NCT02776540 | Ain Shams University |
Ischemic Cerebrovascular Accident
|
June 1, 2016 | Phase 4 |
NCT02230527 | The Cleveland Clinic |
Peripheral Arterial Disease
|
October 2014 | Phase 2|Phase 3 |
NCT01175200 | Ascopharm Groupe Novasco|Groupe Hospitalier Pitie-Salpetriere|Medco Health Solutions, Inc. |
Anti Platelet Effects
|
September 2010 | Not Applicable |
NCT01129388 | Sanofi|Bristol-Myers Squibb |
Healthy
|
March 2009 | Phase 1 |
NCT01626534 | Assistance Publique Hopitaux De Marseille |
Acute Coronary Syndrome
|
March 2012 | Phase 3 |
NCT04305587 | Pfizer |
Diabetes Mellitus Type 2
|
March 16, 2020 | Phase 1 |
NCT01663038 | Chong Kun Dang Pharmaceutical|Inje University |
Coronary Artery Disease
|
December 2010 | Phase 1 |
NCT03357874 | Assistance Publique Hopitaux De Marseille |
Acute Coronary Syndrome
|
October 28, 2018 | Phase 3 |
NCT00249873 | Sanofi|Bristol-Myers Squibb |
Atrial Fibrillation|Vascular Risk
|
June 2003 | Phase 3 |
NCT00642811 | AstraZeneca |
Stable Coronary Artery Disease
|
May 2008 | Phase 2 |
NCT05554822 | Azienda Ospedaliero Universitaria Maggiore della Carita|Abbott Medical Devices |
Left Atrial Appendage Occlusion|Antiplatelet Therapy
|
June 14, 2021 | Phase 3 |
NCT04483583 | University of Florida |
Coronary Artery Disease
|
December 10, 2020 | Phase 4 |
NCT00799045 | Laval University|Sanofi|Bristol-Myers Squibb |
Migraine
|
October 2008 | Phase 4 |
NCT02580149 | Michael Wolzt, Prof. MD|Medical University of Vienna |
Ischemia
|
October 2015 | Phase 4 |
NCT01813435 | ECRI bv|Biosensors International|AstraZeneca|The Medicines Company |
Coronary Artery Disease (CAD)
|
July 1, 2013 | Phase 3 |
NCT01955512 | University of Southampton |
Asthma
|
May 2013 | Phase 2 |
NCT04174261 | Hellenic Society of Interventional Cardiology |
Periprocedural Myocardial Infarction
|
January 29, 2017 | Phase 4 |
NCT02404363 | Assistance Publique - Hôpitaux de Paris|Groupe Francophone Thrombose et Cancer |
Locally Advanced Pancreatic Cancer|Adenocarcinoma, Pancreas|Metastatic Pancreatic Cancer
|
January 11, 2016 | Phase 3 |
NCT02428374 | Federal University of São Paulo|Fundação de Amparo à Pesquisa do Estado de São Paulo |
Myocardial Fibrosis
|
May 2015 | Phase 4 |
NCT02469740 | University Hospital of Limerick |
Myocardial Ischemia|Coronary Artery Disease|Endothelial Dysfunction
|
July 2015 | Phase 4 |
NCT02748330 | Peking Union Medical College Hospital |
Coronary Artery Disease|Diabetes Mellitus, Type 2
|
June 2016 | Phase 4 |
NCT02334254 | Beijing Anzhen Hospital |
Atrial Fibrillation
|
August 2013 | Phase 4 |
NCT01012544 | St. Antonius Hospital|University of Cologne |
Coronary Artery Stent Thrombosis
|
April 2009 | Phase 4 |
NCT05223335 | Mayo Clinic |
Bleeding Complications
|
March 29, 2022 | Phase 4 |
NCT00302913 | University Heart Center Freiburg - Bad Krozingen |
Coronary Artery Disease|Drug Resistance
|
December 2005 | Not Applicable |
NCT00433784 | Hopital du Sacre-Coeur de Montreal |
Coronary Artery Disease|Elective Percutaneous Coronary Intervention
|
September 2004 | Phase 4 |
NCT03661411 | General Hospital of Shenyang Military Region |
Stroke
|
October 17, 2018 | Phase 4 |
NCT02285751 | Medical University of Vienna |
Critical Illness
|
November 2012 | Phase 2 |
NCT00335452 | Sanofi|Bristol-Myers Squibb |
Acute Coronary Disease|Angina Unstable
|
June 2006 | Phase 3 |
NCT01409616 | Astellas Pharma Inc |
Pharmacodynamic Interaction|Healthy Subjects
|
April 2009 | Phase 1 |
NCT04738097 | Mazandaran University of Medical Sciences |
Ischemic Stroke|Transient Ischemic Attack
|
August 8, 2021 | Phase 3 |
NCT01192724 | Yonsei University |
Coronary Artery Disease
|
March 2010 | Phase 4 |
NCT00821834 | Sanofi |
Stable Angina|Myocardial Infarction
|
December 2008 | Phase 3 |
NCT02086903 | Dong-A University |
Pharmacodynamics
|
February 2014 | Phase 3 |
NCT00363753 | University of California, San Diego |
Transient Ischemic Attack|Stroke|Aspirin|Clopidogrel
|
August 2006 | Phase 1 |
NCT02817789 | University Hospital, Bordeaux |
Aortic Valve Stenosis
|
May 9, 2016 | Phase 3 |
NCT02944123 | Dong-A University |
Acute Coronary Syndrome
|
September 2016 | Phase 3 |
NCT00889044 | Sheba Medical Center |
Platlet Aggregation|Major Bleeding Outcomes
|
April 2009 | Phase 3 |
NCT01905566 | CHEOL WHAN LEE, M.D., Ph.D|AstraZeneca|CardioVascular Research Foundation, Korea|Asan Medical Center |
Plaque, Atherosclerotic
|
September 2013 | Phase 4 |
NCT02054663 | Ottawa Heart Institute Research Corporation |
Acute Coronary Syndrome
|
December 2013 | Phase 4 |
NCT00942175 | Takeda |
Healthy
|
December 2009 | Phase 1 |
NCT04434365 | Peking Union Medical College Hospital |
Stable Coronary Artery Disease|Percutaneous Coronary Intervention
|
June 21, 2019 | Phase 1|Phase 2 |
NCT01146301 | R&D Cardiologie |
Carotid Stenosis
|
March 2008 | Phase 4 |
NCT01069302 | Takeshi Morimoto|Kyoto University, Graduate School of Medicine |
Coronary Artery Disease
|
February 2010 | Phase 4 |
NCT02048228 | Chinese PLA General Hospital |
CLOPIDOGREL, POOR METABOLISM of (Disorder)
|
October 2014 | Phase 2|Phase 3 |
NCT00977938 | Baim Institute for Clinical Research|Abbott|Boston Scientific Corporation|Bristol-Myers Squibb|Sanofi-Synthelabo|Cordis Corporation|Eli Lilly and Company|Daiichi Sankyo, Inc.|Medtronic |
Coronary Artery Disease
|
October 2009 | Phase 4 |
NCT02869009 | General Hospital of Shenyang Military Region |
Ischemic Stroke
|
November 2016 | Early Phase 1 |
NCT02696226 | The Cleveland Clinic |
Aortic Valve Disorder
|
February 2016 | Not Applicable |
NCT03947229 | Yonsei University |
Coronary Artery Disease|DES
|
August 14, 2019 | Phase 4 |
NCT04333407 | Imperial College London |
COVID-19
|
April 3, 2020 | Not Applicable |
NCT00222261 | Ullevaal University Hospital|The Norwegian Council for Cardiovascular Diseases.|Ada and Hagbart Waages Humanitarian and Charity Foundation|Alf and Aagot Helgesens Research Foundation.|Oslo University Hospital |
Coronary Heart Disease|Angina Pectoris|Atherosclerosis
|
April 2003 | Phase 4 |
NCT04057300 | McGill University Health Centre+Research Institute of the McGill University Health Centre|Canadian Institutes of Health Research (CIHR) |
Acute Coronary Syndrome
|
October 1, 2018 | Phase 4 |
NCT04171687 | HK inno.N Corporation |
Healthy
|
October 21, 2019 | Phase 1 |
NCT02663713 | University of Patras|AstraZeneca |
Myocardial Infarction|Diabetes Mellitus|Renal Disease|Coronary Artery Disease
|
January 2017 | Phase 4 |
NCT00910299 | Eli Lilly and Company|Daiichi Sankyo Co., Ltd. |
Coronary Artery Disease (CAD)
|
July 2009 | Phase 2 |
NCT01621750 | Dr. Reddy´s Laboratories Limited |
Fasting
|
August 2008 | Phase 1 |
NCT02983214 | University of Ioannina|LIBYTEC Pharmaceutical S.A. |
Ischemic Stroke|Peripheral Artery Disease|Diabetes Mellitus, Type 2
|
November 2016 | Phase 4 |
NCT02070159 | Dong-A University |
Coronary Artery Disease
|
December 2011 | Phase 3 |
NCT00385944 | Eli Lilly and Company|Daiichi Sankyo, Inc. |
Acute Coronary Syndrome
|
March 2007 | Phase 2 |
NCT02394145 | Kyunghee University Medical Center |
Chronic Kidney Disease
|
September 2009 | Phase 3 |
NCT03150680 | AHEPA University Hospital|LABNET IAE - Private Reference Diagnostic Laboratory |
Coronary Artery Disease
|
September 1, 2017 | |
NCT02675205 | Fondation Ophtalmologique Adolphe de Rothschild |
Cerebral Aneurysm
|
December 2015 | Phase 3 |
NCT00528411 | AstraZeneca |
Coronary Artery Disease
|
October 2007 | Phase 2 |
NCT03698513 | Bristol-Myers Squibb |
Healthy Volunteers
|
October 4, 2018 | Phase 1 |
NCT02327624 | Sheffield Teaching Hospitals NHS Foundation Trust|AstraZeneca |
Coronary Artery Disease
|
June 2015 | Phase 4 |
NCT01505790 | Assistance Publique Hopitaux De Marseille |
Acute Coronary Syndromes
|
July 2011 | Phase 3 |
NCT01447563 | Hospital Universitario Dr. Jose E. Gonzalez |
Comparative Bioavailability of Clopidogrel Tablets
|
May 2008 | Phase 1 |
NCT02224131 | Beijing Tiantan Hospital |
Embolic Stroke
|
January 2015 | Phase 4 |
NCT00734123 | Hospital Arnau de Vilanova|Pfizer |
Atherosclerosis|Cardiovascular Diseases
|
April 2008 | Phase 4 |
NCT00858715 | Medical University of Vienna |
Atherosclerosis|Angioplasty
|
May 2008 | Not Applicable |
NCT01706510 | Rapid City Regional Hospital, Inc|AstraZeneca |
Coronary Artery Disease
|
December 2012 | Phase 4 |
NCT02201667 | RenJi Hospital |
Acute Coronary Syndrome
|
August 2014 | Phase 4 |
NCT00822666 | Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France |
Coronary Artery Disease
|
October 2008 | Phase 3 |
NCT01506713 | Dr. Reddy´s Laboratories Limited |
Fasting
|
September 2006 | Phase 1 |
NCT02233790 | First Hospital of China Medical University|AstraZeneca |
Myocardial Infarction|No-Reflow Phenomenon
|
December 2014 | Phase 4 |
NCT02548611 | LMU Klinikum |
Angina Pectoris
|
September 2015 | Phase 4 |
NCT00228423 | Ottawa Heart Institute Research Corporation|Sanofi|Bristol-Myers Squibb |
Atherosclerosis
|
May 2006 | Phase 2 |
NCT00152646 | University Hospital, Angers |
Peripheral Arterial Disease
|
March 2005 | Phase 4 |
NCT00163267 | University Hospital Tuebingen |
Peripheral Vascular Diseases
|
September 2005 | Phase 2|Phase 3 |
NCT02567461 | University of Florida|Daiichi Sankyo, Inc. |
Coronary Artery Disease
|
March 2016 | Phase 4 |
NCT03814642 | HK inno.N Corporation |
Healthy
|
January 21, 2019 | Phase 1 |
NCT02829151 | Yonsei University |
Critical Limb Ischemia
|
February 21, 2017 | Phase 4 |
NCT03054207 | Jules Desmeules|University Hospital, Geneva |
Hiv
|
June 2015 | Phase 1 |
NCT01174693 | Gangnam Severance Hospital|Myung In Pharmaceutical Company|Yonsei University |
Cerebral Infarction
|
March 2010 | Phase 4 |
NCT02742987 | Campus Bio-Medico University |
Coronary Artery Disease|Diabetes Mellitus
|
March 2014 | Phase 4 |
NCT01684813 | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla|Andaluz Health Service |
Diabetes Mellitus Type II|Acute Coronary Syndrome
|
October 2012 | Phase 4 |
NCT02211066 | Hospital Clinic of Barcelona|AstraZeneca |
Patients Who Are Scheduled to Undergo a PCI (Percutaneous Coronary Intervention) for CTO (Chronic Total Occlusion)
|
October 2014 | Phase 4 |
NCT00432120 | Charles University, Czech Republic |
Ischemic Heart Disease
|
March 2006 | Phase 3 |
NCT00797056 | Washington University School of Medicine |
Peripheral Vascular Diseases
|
April 2008 | Early Phase 1 |
NCT03385538 | Zealand University Hospital |
Ischemic Stroke
|
November 1, 2015 | Phase 4 |
NCT02505399 | University Hospital, Toulouse |
Atherosclerosis
|
November 2015 | Phase 4 |
NCT01283282 | Emory University |
Coronary Artery Disease
|
January 2008 | Phase 4 |
NCT01598337 | Prince Sultan Cardiac Center, Adult Cardiology Department. |
Coronary Artery Disease
|
April 2011 | Phase 3 |
NCT04368377 | University of Milan|Fondazione Un Cuore per Milano - a no profit foundation |
Pneumonia, Viral|Corona Virus Infection|Respiratory Failure|Embolism and Thrombosis
|
April 6, 2020 | Phase 2 |
NCT01959451 | LMU Klinikum |
Acute Coronary Syndrome
|
September 2013 | Phase 4 |
NCT02699008 | Wuhan Asia Heart Hospital |
Acute Coronary Syndrome
|
January 2014 | Not Applicable |
NCT00020189 | National Cancer Institute (NCI) |
Head and Neck Cancer|Thromboembolism
|
June 2000 | Phase 2 |
NCT00775762 | Catholic University of the Sacred Heart |
Polyvascular Disease|Cardiovascular Disease
|
November 2008 | Phase 3 |
NCT00648947 | Mylan Pharmaceuticals Inc|MylanPharma |
Healthy
|
December 2004 | Phase 1 |
NCT01979445 | The Medicines Company |
Coronary Artery Disease (CAD)
|
December 2, 2013 | Phase 2 |
NCT01930591 | Unity Health Toronto|Prairie Vascular Research Inc. |
Acute Myocardial Infarction
|
May 2014 | Phase 3 |
NCT02224066 | Hospital de Meixoeiro |
Severe Aortic Valve Stenosis|Transcatheter Aortic Valve Implantation|Transcatheter Aortic Valve Replacement
|
January 2016 | Phase 4 |
NCT01777503 | Arcispedale Santa Maria Nuova-IRCCS|ANMCO Italian Association of Hospital Cardiologist|Italian Society of Invasive Cardiology |
Acute Coronary Syndrome|Coronary Arteriosclerosis|Myocardial Ischemia|Cardiovascular Diseases
|
November 2012 | Phase 4 |
NCT01523366 | AstraZeneca |
Stable Coronary Artery Disease
|
April 2012 | Phase 4 |
NCT02411903 | The Third Affiliated Hospital of Guangzhou Medical University |
Cerebral Infarction|Clopidogrel,Poor Metabolism of (Disorder)
|
March 2015 | Phase 4 |
NCT02433587 | University Hospitals Cleveland Medical Center |
Peripheral Arterial Disease|Endovascular Procedures
|
October 2019 | Phase 3 |
NCT00714961 | Sanofi|Bristol-Myers Squibb |
Acute Coronary Syndromes
|
February 2003 | Phase 3 |
NCT00816166 | Codman & Shurtleff |
Ischemic Stroke|Transient Ischemic Attack
|
October 2008 | Phase 2|Phase 3 |
NCT02494284 | CHEOL WHAN LEE, M.D., Ph.D|CardioVascular Research Foundation, Korea|Medtronic|Chong Kun Dang Pharmaceutical Corp.|Asan Medical Center |
Coronary Artery Disease
|
December 22, 2015 | Phase 4 |
NCT00391872 | AstraZeneca |
Acute Coronary Syndrome
|
October 2006 | Phase 3 |
NCT01422109 | Yuhan Corporation |
Acute Coronary Syndrome
|
July 2011 | Phase 1 |
NCT00343876 | Intermountain Health Care, Inc.|Bristol-Myers Squibb|Sanofi-Synthelabo |
Coronary Artery Disease
|
July 2005 | Phase 4 |
NCT00693069 | Hopital du Sacre-Coeur de Montreal |
Coronary Artery Disease
|
September 2004 | Phase 3 |
NCT01806090 | Chinese University of Hong Kong |
Gastrointestinal Bleeding
|
February 2012 | Phase 4 |
NCT00684203 | Merck Sharp & Dohme LLC |
Atherosclerosis|Myocardial Ischemia|Myocardial Infarction
|
December 1, 2006 | Phase 2 |
NCT00776633 | Deutsches Herzzentrum Muenchen |
Coronary Artery Disease|Atrial Fibrillation
|
September 2008 | Phase 4 |
NCT04409834 | The TIMI Study Group |
COVID-19|Venous Thromboembolism|Arterial Thrombosis
|
August 5, 2020 | Phase 4 |
NCT01212302 | Ruhr University of Bochum |
Coronary Artery Disease
|
October 2008 | Not Applicable |
NCT03942458 | Jiangsu vcare pharmaceutical technology co., LTD |
Healthy Subjects|PK+PD
|
April 3, 2019 | Phase 1 |
NCT00105209 | Kawut, Steven, MD|National Heart, Lung, and Blood Institute (NHLBI)|Columbia University |
Hypertension, Pulmonary
|
April 2002 | Phase 2 |
NCT00360386 | Sanofi|Bristol-Myers Squibb |
Ischemia
|
March 2004 | Phase 2 |
NCT01129414 | Sanofi|Bristol-Myers Squibb |
Healthy
|
June 2009 | Phase 1 |
NCT01950416 | University of Patras |
ST Elevation Myocardial Infarction|Fibrinolysis|P2Y12 Inhibitor
|
March 2013 | Phase 4 |
NCT01482117 | Inje University |
Interaction
|
November 2011 | Not Applicable |
NCT01512485 | Dr. Reddy´s Laboratories Limited |
Healthy
|
October 2006 | Phase 1 |
NCT03568890 | Centre de Recherche de l´Institut Universitaire de Cardiologie et de Pneumologie de Quebec|Institut universitaire de cardiologie et de pneumologie de Québec, University Laval |
Left Atrial Appendage Closure|Thrombosis|Stroke|TIA|Bleeding
|
September 1, 2018 | Phase 4 |
NCT00853450 | AstraZeneca |
Antiplatelet Effect
|
February 2009 | Phase 1 |
NCT00396877 | Sanofi|Bristol-Myers Squibb |
Heart Defects, Congenital
|
November 2006 | Phase 3 |
NCT01768637 | University of Texas Southwestern Medical Center|American Heart Association |
Chronic Kidney Disease
|
January 2013 | Phase 1 |
NCT02222987 | Boehringer Ingelheim |
Healthy
|
February 1999 | Phase 1 |
NCT03775746 | East and North Hertfordshire NHS Trust|University of Hertfordshire |
Acute Coronary Syndrome
|
January 8, 2019 | Phase 4 |
NCT02989558 | University of Athens |
Aortic Valve Stenosis
|
December 2016 | Phase 3 |
NCT05210595 | Dong-A University |
Acute Myocardial Infarction|Ticagrelor
|
January 1, 2022 | Phase 4 |
NCT01335048 | Ospedale Misericordia e Dolce |
Stable Angina
|
April 2011 | Phase 4 |
NCT00059306 | University of British Columbia|National Institute of Neurological Disorders and Stroke (NINDS) |
Cerebrovascular Accident|Hypertension
|
February 2003 | Phase 3 |
NCT00243178 | Sanofi|Bristol-Myers Squibb |
Atrial Fibrillation|Vascular Risk
|
July 2003 | Phase 3 |
NCT04219774 | Duke University |
Cognition Disorder|Stroke|Occlusion Carotid
|
January 4, 2019 | Phase 2 |
NCT01995370 | Japan Cardiovascular Research Foundation|Otsuka Pharmaceutical Co., Ltd. |
Noncardioembolic Cerebral Infarction
|
December 13, 2013 | Phase 4 |
NCT01107899 | Eli Lilly and Company|Daiichi Sankyo Co., Ltd. |
Acute Coronary Syndromes
|
October 2009 | Phase 1 |
NCT02640794 | Centre de Recherche de l´Institut Universitaire de Cardiologie et de Pneumologie de Quebec|Institut universitaire de cardiologie et de pneumologie de Québec, University Laval |
Aortic Valve Disease|Myocardial Infarction|Stroke|Bleeding
|
January 2015 | Phase 4 |
NCT01630642 | Torrent Pharmaceuticals Limited |
Healthy
|
Phase 1 | |
NCT01123824 | Sanofi|Bristol-Myers Squibb |
Healthy
|
April 2009 | Phase 1 |
NCT05122741 | University of Messina|Natasha Irrera|Gianluca Di Bella|Antonio Micari|Roberto Licordari |
Myocardial Infarction|Myocardial Fibrosis|Myocardial Remodeling, Ventricular
|
December 1, 2021 | |
NCT01210339 | AstraZeneca |
Healthy Volunteers
|
November 2010 | Phase 1 |
NCT00648453 | Sanofi|Bristol-Myers Squibb |
Peripheral Arterial Disease
|
December 2002 | Phase 4 |
NCT01661322 | University of Nottingham |
Stroke
|
April 2009 | Phase 3 |
NCT02439190 | Bristol-Myers Squibb |
Thrombosis
|
September 2015 | Phase 1 |
NCT01264640 | University of Rostock |
Healthy Volunteers
|
July 2010 | Not Applicable |
NCT05546320 | Chinese Academy of Medical Sciences, Fuwai Hospital |
Patent Foramen Ovale|Migraine
|
October 15, 2022 | Phase 4 |
NCT01465828 | Gennaro Sardella|University of Roma La Sapienza |
Acute Coronary Syndrome
|
October 2011 | Phase 3 |
NCT02331511 | Shahid Beheshti University of Medical Sciences |
Complication of Cardiac Defibrillator|Disorder of Cardiac Pacemaker System|Venous Occlusion
|
October 2015 | Not Applicable |
NCT01961856 | University of Patras |
Platelet Reactivity
|
September 2013 | Phase 3 |
NCT02938182 | First Affiliated Hospital Xi´an Jiaotong University |
Migraine
|
October 2016 | Phase 4 |
NCT00640679 | Deutsches Herzzentrum Muenchen |
Coronary Artery Disease
|
April 2008 | Phase 4 |
NCT02320357 | University Hospital, Bordeaux|Ministry for Health and Solidarity, France |
Systemic Lupus Erythematous
|
August 19, 2015 | Phase 1|Phase 2 |
NCT01774838 | University of Cologne |
Acute Coronary Syndrome|Unstable Angina
|
October 2014 | Phase 3 |
NCT01603342 | Novo Nordisk A+S |
Haemostasis|Healthy
|
December 2007 | Phase 1 |
NCT01011257 | Neil Kleiman, MD|The Methodist Hospital Research Institute |
Coronary Artery Disease
|
September 2009 | Phase 4 |
NCT03759067 | Korea University Anam Hospital |
Angina, Stable
|
October 18, 2010 | Not Applicable |
NCT00781573 | North Texas Veterans Healthcare System |
Myocardial Infarction
|
September 11, 2008 | Not Applicable |
NCT03823274 | Yuhan Corporation |
Ischemic Stroke
|
April 1, 2019 | |
NCT01896557 | University of Sao Paulo General Hospital|InCor Heart Institute |
Coronary Artery Disease|Drug Interaction Potentiation
|
October 2011 | Phase 4 |
NCT02093299 | Zealand University Hospital |
Stroke
|
December 2012 | |
NCT03088072 | Scripps Health|Daiichi Sankyo, Inc. |
Non-Valvular Atrial Fibrillation|Left Atrial Appendage Closure
|
March 23, 2017 | Phase 4 |
NCT01121224 | VA Office of Research and Development |
Saphenous Vein Graft Atherosclerosis
|
January 11, 2012 | Phase 4 |
NCT05047172 | University of Florida|National Institute of Neurological Disorders and Stroke (NINDS)|University of Cincinnati|Medical University of South Carolina|Janssen Scientific Affairs, LLC|AstraZeneca |
Intracranial Arteriosclerosis|Stroke
|
August 2, 2022 | Phase 3 |
NCT00935506 | Bristol-Myers Squibb |
Cardiovascular Disease
|
July 2009 | Phase 1 |
NCT05359224 | Yonsei University|Severance Hospital|Gangnam Severance Hospital|Bucheon St. Mary´s Hospital|International St. Mary´s Hospital|Ewha Woman´s University Seoul Hospital |
Intracranial Aneurysm
|
June 13, 2022 | Phase 4 |
NCT01758614 | Xuanwu Hospital, Beijing |
Carotid Artery Occlusion|Middle Cerebral Artery Occlusion|Stroke
|
June 6, 2013 | Phase 3 |
NCT00109382 | University of Calgary|Canadian Institutes of Health Research (CIHR)|Canadian Stroke Consortium (CSC) |
Transient Ischemic Attack|Stroke
|
May 2003 | Phase 2|Phase 3 |
NCT01106534 | Abbott Medical Devices|Baim Institute for Clinical Research|Bristol-Myers Squibb|Eli Lilly and Company|Daiichi Sankyo, Inc. |
Chronic Total Occlusion of Coronary Artery|Vascular Disease|Myocardial Ischemia|Coronary Artery Stenosis|Coronary Disease|Coronary Artery Disease|Coronary Restenosis
|
August 2009 | Phase 4 |
NCT01014624 | Daiichi Sankyo, Inc. |
Coronary Artery Disease
|
February 2010 | Phase 4 |
NCT00669149 | Centre Hospitalier de PAU |
Coronary Artery Disease
|
June 2008 | Phase 4 |
NCT04661709 | Guang´anmen Hospital of China Academy of Chinese Medical Sciences|Special Project of National Traditional Chinese Medicine Clinical Research Base of State Administration of Traditional Chinese Medicine|National Natural Science Foundation of China |
Coronary Heart Disease|Unstable Angina|Chinese Herbal Medicine
|
March 1, 2021 | Phase 4 |
NCT02224534 | Gyeongsang National University Hospital|Chinese PLA General Hospital|Chungnam National University Hospital|Pusan National University Yangsan Hospital|National University Heart Centre, Singapore|Ulsan University Hospital|Kyungpook National University Hospital|Samsung Changwon Hospital|Kyunghee University Medical Center|Chungbuk National University Hospital|Chonnam National University Hospital|Seoul National University Bundang Hospital |
ST Elevation Myocardial Infarction
|
October 2014 | Phase 4 |
NCT00724880 | Catharina Ziekenhuis Eindhoven |
Coronary Artery Disease
|
June 2006 | Phase 4 |
NCT01159639 | University of Zagreb |
Coronary Artery Disease|Aspirin Resistance
|
June 2010 | Phase 4 |
NCT02966119 | University Hospital, Lille|Région Hauts de France, France|Ministry of Health, France |
Cerebral Hemorrhage
|
December 7, 2016 | Phase 3 |
NCT02639143 | First Affiliated Hospital of Harbin Medical University |
Inflammation|Thrombosis
|
December 2015 | Phase 4 |
NCT02171598 | Boehringer Ingelheim |
Healthy
|
February 2009 | Phase 1 |
NCT03599284 | Jiangsu vcare pharmaceutical technology co., LTD |
Coronary Artery Disease|Percutaneous Coronary Intervention|Platelet Aggregation Inhibitors
|
August 30, 2018 | Phase 2 |
NCT01955642 | Centre Hospitalier Universitaire de Saint Etienne|Groupe de Recherche sur la Thrombose |
Brain Ischemia|Ischemic Attack
|
September 2013 | |
NCT04431349 | Ajou University School of Medicine |
Blood Loss, Surgical|Ticagrelor|Clopidogrel
|
January 1, 2016 | |
NCT04937699 | Second Affiliated Hospital, School of Medicine, Zhejiang University |
Acute Coronary Syndrome|Percutaneous Coronary Intervention
|
January 2023 | Phase 4 |
NCT01156571 | The Medicines Company |
Atherosclerosis|Percutaneous Coronary Intervention|Acute Coronary Syndrome
|
September 2010 | Phase 3 |
NCT04850417 | Spanish Society of Cardiology|Instituto de Investigación Sanitaria Hospital Universitario de la Princesa|Fundación de Investigación Biomédica - Hospital Universitario de La Princesa |
Spontaneous Coronary Artery Dissection
|
April 30, 2021 | Phase 4 |
NCT04805710 | Shenyang Northern Hospital |
Rivaroxaban
|
March 17, 2021 | Phase 4 |
NCT00698607 | Seoul National University Hospital|Abbott|Boston Scientific Corporation |
Coronary Artery Disease
|
June 2008 | Phase 4 |
NCT01700322 | Johannes Gutenberg University Mainz |
Coronary Artery Disease
|
August 2012 | Phase 4 |
NCT00830960 | Eli Lilly and Company|Daiichi Sankyo Co., Ltd. |
Acute Coronary Syndrome
|
February 2009 | Phase 3 |
NCT04824911 | Chang Gung Memorial Hospital |
Acute Stroke|Dual Antiplatelet Therapy|Statin
|
March 23, 2021 | Phase 2 |
NCT01830491 | Hanmi Pharmaceutical Company Limited |
Coronary Artery Disease (CAD)
|
March 2009 | Phase 4 |
NCT01955200 | The First Affiliated Hospital with Nanjing Medical University|National Natural Science Foundation of China |
Coronary Artery Disease
|
October 5, 2013 | Phase 4 |
NCT02959606 | Seoul National University Hospital |
Peripheral Arterial Disease
|
December 2016 | Phase 4 |
NCT00778193 | Research Associates of New York, LLP |
Gastroduodenal Ulcer
|
October 2007 | Phase 4 |
NCT00728156 | Newcastle-upon-Tyne Hospitals NHS Trust|British Heart Foundation|University of Newcastle Upon-Tyne |
Type 2 Diabetes Mellitus|Coronary Artery Disease
|
August 2009 | Phase 4 |
NCT02514642 | First Affiliated Hospital of Harbin Medical University |
Coronary Artery Disease
|
July 2015 | Phase 4 |
NCT04001894 | First Affiliated Hospital of Harbin Medical University |
Platelet Reactivity
|
July 2, 2019 | Phase 4 |
NCT04165629 | Clinical Centre of Serbia |
Peripheral Artery Disease|Critical Limb Ischemia|Claudication, Intermittent
|
January 1, 2020 | |
NCT00330772 | Hamilton Health Sciences Corporation|Bristol-Myers Squibb|McMaster University |
Coronary Artery Disease|Coronary Artery Bypass Grafting
|
July 2006 | Phase 3 |
NCT05553613 | Kafrelsheikh University |
Ischemic Stroke
|
October 17, 2022 | Phase 3 |
NCT05098704 | University Hospital, Bordeaux|Ministry for Health and Solidarity, France |
Scleroderma|Systemic Sclerosis
|
June 22, 2022 | Phase 2|Phase 3 |
NCT03430661 | Idorsia Pharmaceuticals Ltd. |
Healthy
|
January 24, 2018 | Phase 1 |
NCT03072121 | Jun Li|Shanghai Hutchison Pharmaceuticals Limited|Guang´anmen Hospital of China Academy of Chinese Medical Sciences |
Coronary Artery Disease(CAD)
|
June 2017 | Phase 4 |
NCT02831218 | Seung-Jung Park|CardioVascular Research Foundation, Korea|Asan Medical Center |
Percutaneous Transluminal Coronary Angioplasty
|
December 2016 | Not Applicable |
NCT01263093 | Eli Lilly and Company |
Major Depressive Disorder
|
December 2010 | Phase 1 |
NCT05573958 | Sarmad Zahoor|University of Managemant and Technology, Pakistan|Mayo Hospital Lahore|Punjab Institute of Cardology |
Acute Coronary Syndrome
|
October 1, 2022 | Phase 4 |
NCT01894789 | Ottawa Heart Institute Research Corporation |
Coronary Artery Disease
|
March 2013 | Phase 2|Phase 3 |
NCT01627431 | University of Roma La Sapienza|University of Florence |
Peripheral Arterial Disease
|
July 2012 | Phase 4 |
NCT01023360 | National Taiwan University Hospital|Haemonetics Corporation |
30 Healthy People
|
May 2008 | Phase 4 |
NCT01790997 | Dexa Medica Group |
Acute Ischemic Stroke
|
May 2012 | Phase 3 |
NCT02925923 | University of Alabama at Birmingham |
Acute Coronary Syndrome|Angina, Unstable
|
November 1, 2016 | Phase 2 |
NCT04946734 | Guangdong Provincial People´s Hospital |
PFO - Patent Foramen Ovale|Migraine
|
July 15, 2021 | Phase 3 |
NCT02379676 | Kiyuk Chang|AstraZeneca|Seoul St. Mary´s Hospital |
Endothelial Dysfunction|Vascular Inflammation
|
January 2015 | Phase 4 |
NCT02044250 | Seoul National University Hospital|Chong Kun Dang Pharmaceutical|Samjin Pharmaceutical Co., Ltd.|Daewoong Pharmaceutical Co. LTD.|Hanmi Pharmaceutical co., ltd. |
Coronary Heart Disease
|
February 2014 | Phase 4 |
NCT02578706 | Icahn School of Medicine at Mount Sinai|National Heart, Lung, and Blood Institute (NHLBI) |
HIV-1 Infection
|
October 2015 | Phase 2 |
NCT01129063 | Sanofi|Bristol-Myers Squibb |
Healthy
|
March 2009 | Phase 1 |
NCT01115738 | Eli Lilly and Company |
Acute Coronary Syndrome
|
May 2010 | Phase 2 |
NCT02044146 | Ottawa Heart Institute Research Corporation|Canadian Institutes of Health Research (CIHR) |
Acute Coronary Syndrome|Percutaneous Coronary Intervention
|
September 2014 | Phase 2|Phase 3 |
NCT02939872 | Seung-Jung Park|CardioVascular Research Foundation, Korea|Asan Medical Center |
Percutaneous Transluminal Coronary Angioplasty|Coronary Disease
|
March 9, 2017 | Phase 4 |
NCT01371058 | Shenyang Northern Hospital |
Coronary Artery Disease
|
March 2011 | Phase 4 |
NCT02247128 | St. Antonius Hospital |
Aortic Valve Disease|Myocardial Infarction|Stroke|Bleeding
|
January 2014 | Phase 4 |
NCT03078465 | Nanjing First Hospital, Nanjing Medical University |
Coronary Artery Disease
|
June 20, 2017 | Phase 3 |
NCT01147588 | AstraZeneca |
Healthy
|
May 2010 | Phase 1 |
NCT01815008 | Johns Hopkins University |
Platelet Aggregation|Platelet Transcriptome|Coronary Artery Disease
|
October 2012 | Phase 4 |
NCT01463150 | University of Patras |
Platelet Reactivity
|
October 2011 | Phase 4 |
NCT01612884 | Indiana University |
Thrombosis|Coronary Artery Disease
|
August 2011 | Phase 4 |
NCT00174759 | Sanofi|Bristol-Myers Squibb |
Arterial Occlusive Diseases
|
September 2004 | Phase 3 |
NCT01381185 | University Hospital Ostrava |
Acute Myocardial Infarction
|
May 2011 | Phase 4 |
NCT04250116 | Yonsei University |
Atrial Fibrillation
|
April 28, 2020 | Phase 4 |
NCT01094457 | Shenyang Northern Hospital |
Acute Coronary Syndromes|Percutaneous Coronary Intervention|Clopidogrel Low Responsiveness
|
March 2009 | Phase 4 |
NCT04091074 | Assiut University |
Carotid Stenosis
|
January 1, 2022 | Phase 1 |
NCT01012193 | Gyeongsang National University Hospital |
Coronary Artery Disease|Percutaneous Coronary Intervention
|
January 2008 | Phase 4 |
NCT00357968 | Eli Lilly and Company|Daiichi Sankyo, Inc.|The TIMI Study Group |
Coronary Artery Disease
|
August 2006 | Phase 2 |
NCT02707445 | Korea University Anam Hospital |
Myocardial Ischemia|CLOPIDOGREL, POOR METABOLISM of (Disorder)
|
September 2011 | Not Applicable |
NCT03039205 | University of Sao Paulo|Fundação de Amparo à Pesquisa do Estado de São Paulo |
Platelet Aggregation|Adenosine|Coronary Artery Disease|Kidney Dysfunction|Antiplatelet Therapy
|
November 7, 2017 | Phase 2 |
NCT03667066 | The University of The West Indies |
Platelet Dysfunction
|
September 1, 2017 | |
NCT03197298 | Thorax Centrum Twente |
Acute Coronary Syndrome|Percutaneous Coronary Intervention|Drug-Eluting Stents
|
December 21, 2012 | |
NCT02060786 | Ajou University School of Medicine|Dong-A Pharmaceutical |
Acute Coronary Syndrome
|
October 2010 | Phase 4 |
NCT05166538 | Yonsei University |
Multi Vessel Coronary Artery Disease
|
February 1, 2022 | Phase 4 |
NCT02554721 | Otsuka Pharmaceutical Co., Ltd. |
Healthy
|
August 2015 | Phase 1 |
NCT03496506 | Actelion |
Healthy Subjects
|
March 5, 2018 | Phase 1 |
NCT03062462 | First Affiliated Hospital of Harbin Medical University |
Coronary Artery Disease|Clopidogrel, Poor Metabolism of
|
February 10, 2017 | Phase 2|Phase 3 |
NCT00814268 | Sanofi|Bristol-Myers Squibb |
Stroke
|
December 2008 | Phase 4 |
NCT04116931 | The First Affiliated Hospital with Nanjing Medical University |
Acute Coronary Syndrome (ACS)
|
June 22, 2020 | Phase 4 |
NCT00130039 | Asan Medical Center|Korea Otsuka International Asia Arab |
Cerebral Infarction|Atherosclerosis
|
August 2005 | Phase 4 |
NCT02123004 | Jinan Central Hospital |
ST-Segment Elevation Myocardial Infarction
|
April 2014 | Phase 4 |
NCT00839345 | Charles University, Czech Republic |
Coronary Artery Disease
|
||
NCT02108808 | University of Patras |
Fractional Flow Reserve
|
April 2014 | Phase 4 |
NCT01012219 | Merck Sharp & Dohme LLC |
Primary Hypercholesterolemia|Mixed Hyperlipidemia
|
November 2009 | Phase 1 |
NCT01864005 | AstraZeneca |
Non-ST or ST Elevation Acute Coronary Syndromes
|
May 2013 | Phase 4 |
NCT03190005 | Taipei City Hospital |
Stable Angina
|
January 1, 2017 | |
NCT01738100 | Hyeon-Cheol Gwon|Samsung Medical Center |
ST-Segment Elevation Myocardial Infarction
|
September 2012 | Phase 2 |
NCT01846559 | Sheffield Teaching Hospitals NHS Foundation Trust|University of Sheffield |
Healthy
|
April 2013 | Phase 4 |
NCT05162053 | Jiangsu vcare pharmaceutical technology co., LTD |
Acute Coronary Syndrome
|
December 9, 2021 | Phase 1 |
NCT03078257 | The First Affiliated Hospital with Nanjing Medical University|National Natural Science Foundation of China |
Coronary Artery Disease
|
January 1, 2016 | Phase 1 |
NCT02298088 | Hospital do Coracao |
Acute ST Segment Elevation Myocardial Infarction|Thrombolysis in Myocardial Infarction Flow
|
August 2015 | Phase 3 |
NCT01235351 | The TIMI Study Group|Bristol-Myers Squibb|Sanofi |
Myocardial Infarction|Percutaneous Coronary Intervention
|
October 2010 | Phase 2 |
NCT01260584 | Daiichi Sankyo, Inc. |
Coronary Artery Disease
|
November 2010 | Phase 4 |
NCT03766581 | Bristol-Myers Squibb|Janssen, LP |
Acute Ischemic Stroke|Transient Ischemic Attack (TIA)
|
January 27, 2019 | Phase 2 |
NCT05257824 | Seoul National University Bundang Hospital|Soonchunhyang University Hospital|Soonchunhyang University Cheonan Hospital|Seoul National University Hospital|Pusan National University Yangsan Hospital|Keimyung University Dongsan Medical Center|Seoul St. Mary´s Hospital|Uijeongbu St. Mary´s Hospital|Ajou University School of Medicine|Chungnam National University Sejong Hospital|Severance Hospital|Asan Medical Center|Yonsei University Gangnam Severance Hospital |
Aneurysm Cerebral|Endovascular Procedures
|
June 23, 2022 | Phase 4 |
NCT03614832 | First Affiliated Hospital of Harbin Medical University |
Platelet Reactivity
|
May 1, 2018 | Phase 4 |
NCT04006288 | University of Florida|Janssen, LP |
Coronary Artery Disease
|
September 6, 2019 | Phase 4 |
NCT01097343 | University of North Carolina, Chapel Hill |
Disease Susceptibility
|
March 2010 | Phase 2 |
NCT02446730 | Chonnam National University Hospital |
Cardiac Death|Hemorrhage|Cerebrovascular Accident|Myocardial Infarction
|
September 2014 | Phase 4 |
NCT02486367 | University Hospitals Cleveland Medical Center |
Aortic Stenosis|Inflammation|Thrombosis
|
June 2015 | Phase 4 |
NCT02628587 | Hospital Central San Luis Potosi, Mexico |
Acute Coronary Syndrome
|
February 2016 | Phase 4 |
NCT03119012 | Samsung Medical Center |
Coronary Artery Disease|Stents|Atherosclerosis
|
April 19, 2017 | Phase 4 |
NCT01129375 | Sanofi|Bristol-Myers Squibb |
Healthy
|
February 2009 | Phase 1 |
NCT00262275 | Papworth Hospital NHS Foundation Trust |
Ischemic Heart Disease
|
July 2002 | Not Applicable |
NCT02026219 | Inha University Hospital |
Non-ST Segment Elevation Myocardial Infarction|ST Segment Elevation Myocardial Infarction
|
October 2013 | Phase 4 |
NCT04654052 | Fundación EPIC |
Acute Coronary Syndrome|Acute Myocardial Infarction|Coronary Artery Disease|Percutaneous Coronary Intervention
|
July 2, 2021 | Phase 4 |
NCT02587260 | Erasmus Medical Center|Covance |
Cardiovascular Diseases
|
December 17, 2015 | Phase 4 |
NCT00305162 | The Medicines Company |
Myocardial Infarction (MI)|Acute Coronary Syndromes (ACS)
|
April 2006 | Phase 3 |
NCT01495845 | University of North Carolina, Chapel Hill|Kerr Drug|Laboratory Corporation of America |
Stroke|Transient Ischemic Attack|Myocardial Infarction
|
December 2011 | Phase 1 |
NCT00882388 | Seoul National University Hospital |
Healthy
|
March 2005 | Phase 4 |
NCT01394848 | Yonsei University|OrbusNeich|Yuhan Corporation |
Stable Angina
|
October 2011 | Phase 4 |
NCT04619381 | Vanderbilt University Medical Center |
Coronary Artery Disease
|
March 19, 2021 | |
NCT02319941 | Seung-Jung Park|AstraZeneca|Roche Pharma AG|KBM pharm|Asan Medical Center |
Acute Coronary Syndrome
|
May 20, 2015 | Phase 2 |
NCT02163954 | Kyunghee University Medical Center|Kyunghee University |
Chronic Kidney Disease
|
January 2013 | Phase 3 |
NCT01107912 | Eli Lilly and Company|Daiichi Sankyo Co., Ltd. |
Coronary Artery Disease
|
March 2010 | Phase 1 |
NCT00976092 | Deutsches Herzzentrum Muenchen |
Myocardial Infarction
|
September 2009 | Phase 4 |
NCT03329261 | Laboratoires Teriak |
Diabetes Mellitus, Type 2|NSTEMI - Non-ST Segment Elevation MI|Coronary Angioplasty
|
December 7, 2017 | Phase 4 |
NCT05233124 | Instituto Nacional de Cardiologia Ignacio Chavez |
Acute Coronary Syndrome|Coronary Artery Ectasia
|
September 1, 2021 | Phase 2 |
NCT02140801 | Nanjing First Hospital, Nanjing Medical University |
Thrombosis
|
May 1, 2014 | Phase 4 |
NCT02556203 | Bayer|Janssen Research & Development, LLC |
Transcatheter Aortic Valve Replacement
|
December 16, 2015 | Phase 3 |
NCT01621451 | Asan Medical Center|Takeda |
Early Gastric Cancer|Gastric Dysplasia
|
June 2012 | Phase 4 |
NCT00386191 | Sanofi |
Cerebral Infarction
|
September 2006 | Phase 4 |
NCT02548650 | University of Florida|Merck Sharp & Dohme LLC |
Myocardial Infarction|Diabetes Mellitus|Peripheral Arterial Disease
|
March 25, 2016 | Phase 4 |
NCT01635426 | Ain Shams University |
Recurrent Pregnancy Loss
|
March 2012 | Phase 2|Phase 3 |
NCT04088513 | First Affiliated Hospital, Sun Yat-Sen University |
G6PD Deficiency|Stroke
|
January 22, 2020 | Phase 4 |
NCT02419820 | IlDong Pharmaceutical Co Ltd|Asan Medical Center |
Acute Coronary Syndrome
|
March 2015 | Phase 1 |
NCT03613857 | Cairo University |
Myocardial Infarction
|
April 15, 2017 | |
NCT00979589 | Beijing Tiantan Hospital|University of California, San Francisco |
Stroke|Transient Ischemic Attack
|
December 2009 | Phase 3 |
NCT05516784 | Universiti Sains Malaysia |
Coronary Artery Disease (CAD)
|
September 1, 2019 | Phase 4 |
NCT00696566 | Sheffield Teaching Hospitals NHS Foundation Trust|British Heart Foundation|University of Sheffield |
Coronary Artery Disease
|
November 2007 | Phase 1 |
NCT00619073 | University of Massachusetts, Worcester|Sanofi|Bristol-Myers Squibb |
Blood Platelets|Clopidogrel
|
April 2008 | Not Applicable |
NCT00494156 | C. Clay Cothren, MD|Denver Health and Hospital Authority |
Carotid Artery Injury|Vertebral Artery Injury
|
July 2003 | Not Applicable |
NCT00418860 | Samsung Medical Center|Medtronic |
Coronary Artery Disease
|
September 2006 | Not Applicable |
NCT00944333 | Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS |
Angina Pectoris|Silent Ischemia
|
July 2009 | Phase 3 |
NCT02121288 | AstraZeneca |
Peripheral Artery Disease|Vascular Disease|Arterial Occlusion Disease|Intermittent Claudication|Ankle Brachial Index (0.9 or Less)
|
December 2014 | Phase 4 |
NCT02164864 | Boehringer Ingelheim |
Atrial Fibrillation|Percutaneous Coronary Intervention
|
July 22, 2014 | Phase 3 |
NCT04369534 | University of Zagreb|Croatian Science Foundation|Clinical Hospital Centre Zagreb |
Acute Coronary Syndrome|STEMI|NSTEMI - Non-ST Segment Elevation MI|PLATELET AGGREGATION|INDIVIDUALIZED THERAPY
|
December 1, 2015 | Phase 4 |
NCT00915733 | Gyeongsang National University Hospital |
Myocardial Infarction
|
May 2009 | Phase 4 |
NCT01572623 | Campus Bio-Medico University |
Carotid Stenosis
|
July 2011 | Phase 4 |
NCT02094963 | Seung-Jung Park|CardioVascular Research Foundation, Korea|Asan Medical Center |
Acute Coronary Syndrome|Myocardial Ischemia|Heart Diseases|Cardiovascular Diseases|Angina Pectoris
|
July 5, 2014 | Phase 4 |
NCT00749710 | Tel-Aviv Sourasky Medical Center |
Femoral Neck Fractures|Pertrochanteric Fractures|Antiaggregant Therapy
|
September 2008 | Not Applicable |
NCT02034292 | IlDong Pharmaceutical Co Ltd|Asan Medical Center |
Acute Coronary Syndrome
|
February 2014 | Phase 1 |
NCT01107925 | Eli Lilly and Company|Daiichi Sankyo Co., Ltd. |
Coronary Artery Disease
|
March 2010 | Phase 1 |
NCT01561950 | Novo Nordisk A+S |
Haemostasis|Healthy
|
May 2008 | Phase 1 |
NCT01341964 | Population Health Research Institute |
Drug Action Increased
|
May 2011 | Phase 4 |
NCT01341600 | University of Maryland, Baltimore|Food and Drug Administration (FDA)|National Cancer Institute (NCI)|National Institute of General Medical Sciences (NIGMS)|National Heart, Lung, and Blood Institute (NHLBI) |
Metabolism of Clopidogrel
|
July 2010 | Not Applicable |
NCT02833948 | ECRI bv|Rigshospitalet, Denmark|Bayer|Cardialysis BV |
Aortic Valve Stenosis|Cardiovascular Diseases|Heart Valve Diseases|Ventricular Outflow Obstruction|Thrombosis
|
May 2016 | Phase 3 |
NCT00882739 | Ospedale San Donato |
Acute Myocardial Infarction
|
April 2009 | Phase 4 |
NCT04142151 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine |
Ischemic Stroke|Antiplatelet Effect
|
September 1, 2019 | Not Applicable |
NCT03961334 | University of Zurich|Swiss National Science Foundation |
Stroke, Ischemic
|
December 5, 2019 | Phase 3 |
NCT03330223 | The First Affiliated Hospital with Nanjing Medical University |
Renal Failure|Coronary Artery Disease|Hemolysis
|
November 10, 2017 | |
NCT02565693 | UMC Utrecht|Dutch Heart Foundation|ZonMw: The Netherlands Organisation for Health Research and Development |
Cerebral Hemorrhage|Atrial Fibrillation
|
September 2014 | Phase 2 |
NCT01155765 | University of Patras |
Hemodialysis|Chronic Renal Failure
|
May 2010 | Phase 3 |
NCT00235950 | AstraZeneca |
Coronary Heart Disease
|
January 2004 | Phase 4 |
NCT01109784 | University of Patras |
Coronary Artery Disease (CAD)|Acute Coronary Syndrome (ACS)
|
April 2010 | Phase 3 |
NCT02447809 | The First Affiliated Hospital with Nanjing Medical University|National Natural Science Foundation of China |
Coronary Artery Disease
|
January 2015 | Phase 4 |
NCT04502017 | Texas Cardiac Arrhythmia Research Foundation |
Device-Related Thrombosis|Atrial Fibrillation|Left Atrial Appendage Occlusion
|
August 5, 2020 | Phase 4 |
NCT03006835 | Xijing Hospital|Shenzhen Salubris Pharmaceuticals Co., Ltd. |
Coronary Heart Disease
|
January 2017 | Phase 4 |
NCT00121446 | University of Alberta|Hoffmann-La Roche|Sanofi|Eli Lilly and Company |
Myocardial Infarction
|
July 2003 | Phase 2|Phase 3 |
NCT01129427 | Sanofi|Bristol-Myers Squibb |
Healthy
|
August 2009 | Phase 1 |
NCT01743014 | AHEPA University Hospital|Aristotle University Of Thessaloniki |
Diabetes Type 2|Diabetic Nephropathy|Vascular Disease
|
July 2012 | Phase 4 |
NCT00817999 | Creighton University |
Healthy
|
November 2008 | Phase 4 |
NCT02287909 | University of Florida |
Coronary Artery Disease
|
December 2014 | Phase 4 |
NCT00059215 | Eli Lilly and Company |
Cardiovascular Diseases|Heart Diseases
|
April 2003 | Phase 2 |
NCT00513149 | National Taiwan University Hospital |
Coronary Artery Disease
|
July 2006 | Phase 4 |
NCT01643031 | Rabin Medical Center|Tel Aviv Medical Center|Sheba Medical Center|Meir Medical Center|Rambam Health Care Campus |
Diabetes Mellitus|Coronary Disease
|
August 2012 | Phase 4 |
NCT02922465 | Kowa Research Institute, Inc. |
Healthy
|
September 2016 | Phase 1 |
NCT03378934 | Peking Union Medical College Hospital |
Coronary Artery Disease|Percutaneous Coronary Intervention
|
September 26, 2018 | Phase 4 |
NCT00644657 | University of Oklahoma |
Coronary Artery Disease|Chest Pain
|
March 2007 | Not Applicable |
NCT01102439 | Population Health Research Institute |
Coronary Artery Disease
|
April 2010 | Phase 4 |
NCT00645918 | Accumetrics, Inc. |
Coronary Arteriosclerosis|Acute Coronary Syndrome
|
June 2008 | Not Applicable |
NCT00356135 | Eli Lilly and Company|Daiichi Sankyo, Inc. |
Coronary Arteriosclerosis|Acute Coronary Syndrome
|
July 2006 | Phase 2 |
NCT02559414 | NYU Langone Health |
HIV|Cardiovascular Diseases|Inflammation
|
February 2015 | Phase 2 |
NCT00862420 | Sanofi |
Peripheral Arterial Disease (PAD)
|
February 2009 | Phase 3 |
NCT02866175 | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company|Daiichi Sankyo, Inc. |
Atrial Fibrillation
|
February 24, 2017 | Phase 3 |
NCT00372216 | Stiftung Institut fuer Herzinfarktforschung|Bristol-Myers Squibb|Sanofi |
Myocardial Infarction
|
October 2006 | Phase 3 |
NCT01609647 | Dong-A University |
Acute Coronary Syndrome
|
September 2012 | Phase 3 |
NCT01094275 | Neil Kleiman, MD|The Methodist Hospital Research Institute |
Coronary Artery Disease
|
January 2010 | |
NCT03150667 | North Texas Veterans Healthcare System |
Chronic Kidney Diseases|Acute Coronary Syndrome
|
April 10, 2017 | Phase 4 |
NCT03072082 | Jun Li|China Academy of Chinese Medical Sciences|Guang´anmen Hospital of China Academy of Chinese Medical Sciences |
Coronary Artery Disease(CAD)
|
June 2017 | Phase 4 |
NCT02032290 | Azienda Policlinico Umberto I |
Acute Coronary Syndrome:|Non ST Elevation Myocardial Infarction|ST Elevation Myocardial Infarction|Unstable Angina
|
February 2014 | Phase 4 |
NCT01630915 | Torrent Pharmaceuticals Limited |
Healthy
|
Phase 1 | |
NCT01636180 | Fundacja O?rodek Bada? Medycznych|KCRI |
Acute Myocardial Infarction
|
March 2012 | Phase 4 |
NCT00954707 | Cordis Corporation |
Coronary Artery Disease
|
August 2009 | Phase 4 |
NCT03774394 | University of Florida|Scott R. MacKenzie Foundation |
Chronic Kidney Disease (CKD)|Type 2 Diabetes Mellitus (T2DM)|Coronary Artery Disease (CAD)
|
August 22, 2019 | Phase 4 |
NCT00325390 | Sanofi|Daiichi Pharmaceuticals |
Platelet Aggregation Inhibitors|NSTEACS
|
July 2004 | Phase 3 |
NCT02010632 | Khon Kaen University |
Pharmacodynamics
|
August 2013 | Phase 1 |
NCT02384070 | Odessa Heart Institute |
Coronary Artery Disease
|
January 2009 | Not Applicable |
NCT00611286 | Marco Valgimigli|Università degli Studi di Ferrara |
Coronary Artery Disease
|
December 2006 | Phase 4 |
NCT02889549 | First Affiliated Hospital of Harbin Medical University |
Coronary Artery Disease
|
August 2016 | Phase 2|Phase 3 |
NCT00050817 | Sanofi |
Arteriosclerosis
|
October 2002 | Phase 3 |
NCT01141153 | Hospital Universitari Vall d´Hebron Research Institute |
Atrial Fibrillation|Stroke
|
June 2010 | Phase 4 |
NCT02931045 | Medical University of Warsaw|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
Myocardial Infarction
|
December 30, 2017 | Phase 4 |
NCT02519608 | University Hospital of Ferrara |
Coronary Artery Disease|Chronic Obstructive Pulmonary Disease
|
September 2015 | Phase 2 |
NCT01603082 | AstraZeneca |
Acute Coronary Syndrome
|
July 2012 | Phase 4 |
NCT01802775 | Daiichi Sankyo, Inc.|UMC Utrecht |
Peripheral Arterial Disease
|
February 6, 2013 | Phase 2 |
NCT02330640 | Chinese Academy of Medical Sciences, Fuwai Hospital |
Antiplatelet Therapy of Coronary Artery Bypass
|
January 2016 | Phase 4 |
NCT01572129 | Campus Bio-Medico University |
Acute Coronary Syndrome|Myocardial Infarction
|
November 2011 | Phase 4 |
NCT01742117 | Mayo Clinic|Spartan Bioscience Inc.|Applied Health Research Centre|National Heart, Lung, and Blood Institute (NHLBI) |
Coronary Artery Disease|Acute Coronary Syndrome|Stenosis
|
May 2013 | Phase 4 |
NCT01812330 | General Hospital of Chinese Armed Police Forces |
Acute Coronary Syndrome
|
January 2013 | Phase 3 |
NCT01960296 | Icahn School of Medicine at Mount Sinai|Doris Duke Charitable Foundation |
Clopidogrel
|
January 2012 | Phase 2 |
NCT02309970 | Rabin Medical Center |
Ischemic Stroke
|
December 2014 |
Oil
Room temperature in continental US; may vary elsewhere.
-20°C, stored under nitrogen, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)
DMSO : 50 mg/mL ( 155.37 mM ; Need ultrasonic)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 3.1073 mL | 15.5366 mL | 31.0733 mL |
5 mM | 0.6215 mL | 3.1073 mL | 6.2147 mL |
10 mM | 0.3107 mL | 1.5537 mL | 3.1073 mL |